Over the past several years, the exciting discoveries in gene and cell therapies have given rise to a surge of new drug development companies resulting in excessive demand for R&D lab and manufacturing space across all significant Life Sciences clusters in the US. This demand has resulted in a race to develop new research and manufacturing space to support these companies as they advance new therapies from molecule to market.
As the impact of SARS-CoV-2/COVID-19 has moved from impending threat to reality, with restrictive measures on community activity becoming more stringent with each passing day, there are many impacts on the Life Sciences Industry, both near and long term. These impacts affect investigations progressing in the labs, expansion plans, development of new facilities, supply chain, the funding ecosystem and the regulatory process.
This new whitepaper "The Impact of SARS-CoV-2 on the Life Sciences Real Estate Sector" addresses five immediate trends we expect to see as we navigate COVID-19.
Joseph Fetterman is a member of Colliers Life Sciences Practice Group. Working together with Michael Brown and Clifford Brechner, the team advises pre-clinical, clinical and mid-sized drug development companies with their real estate and facilities requirements at critical transitions, including initial commercial research and development, clinical trial production, commercial-scale manufacturing, facility disposition and lease restructuring.